Placebo News and Research

RSS

Aradigm fourth quarter revenue is $144,000 for 2010

Aradigm Corporation today announced financial results for the fourth quarter and full year ended December 31, 2010.

24 Mar 2011

Little evidence supporting effectiveness of acupuncture in reducing pain

Although acupuncture is commonly used for pain control, doubts about its effectiveness and safety remain. Investigators from the Universities of Exeter & Plymouth (Exeter, UK) and the Korea Institute of Oriental Medicine (Daejeon, South Korea) critically evaluated systematic reviews of acupuncture as a treatment of pain in order to explore this question.

24 Mar 2011

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis.

24 Mar 2011

Simulated acupuncture can treat nausea effectively in cancer patients undergoing radiotherapy

Simulated acupuncture - sometimes referred to as placebo - is just as beneficial as real acupuncture for treating nausea in cancer patients undergoing radiotherapy, according to a study from Karolinska Institutet and Linköping University in Sweden. Patients, who received only standard care including medications for nausea, felt significant more nausea than patients in both the acupuncture groups.

24 Mar 2011

Study demonstrates superiority of Spiriva over salmeterol in reducing risk of exacerbations in COPD

Results of the one-year Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD®) study, published today by the New England Journal of Medicine (NEJM), demonstrate that Spiriva® (tiotropium), is superior to salmeterol, in reducing the risk of exacerbations in Chronic Obstructive Pulmonary Disease (COPD).

24 Mar 2011

Opexa's Tovaxin data against MS to be presented at AAN Annual Meeting

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the Company has been selected to present key Tovaxin data at the upcoming American Academy of Neurology 63rd Annual Meeting to be held in Honolulu, Hawaii April 9-16, 2011.

24 Mar 2011

Rapid treatment within an hour of injury dramatically cuts bleeding deaths in injured patients

An hour can make the difference between life and death when using tranexamic acid to treat injured patients with severe bleeding, a study by researchers at the London School of Hygiene & Tropical Medicine suggests.

24 Mar 2011

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has enrolled 33 percent of the total projected patients required for its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

24 Mar 2011

Cilag, POZEN enter license agreement to develop and commercialize MT 400

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has entered into a license agreement with Cilag GmbH International, a division of Johnson & Johnson, for the development and commercialization of MT 400 in Brazil, Colombia, Ecuador and Peru.

23 Mar 2011

Jefferson begins patient recruitment for new clinical trail to prevent colon cancer

Thomas Jefferson University has started recruiting patients for a new National Cancer Institute-sponsored clinical trial to test whether the cholesterol-reducing drug rosuvastatin is effective in the prevention of recurrent colon cancer.

23 Mar 2011

MD Anderson receives $2.7 million NCI grant for acupuncture study in cancer

The University of Texas MD Anderson Cancer Center has been awarded a grant to study whether xerostomia, a debilitating side effect caused by head and neck cancer radiation treatment, can be prevented when acupuncture is part of a patient's treatment regimen.

23 Mar 2011

Corticosteroids may decrease occurrence of hospital-acquired pneumonia in ICU patients

Patients admitted to a hospital with major trauma and treated with the steroid hydrocortisone were less likely to be diagnosed with hospital-acquired pneumonia than patients who received placebo, according to a study in the March 23/30 issue of JAMA.

23 Mar 2011

Use of fibrates for high lipid levels increases despite uncertain improvement in clinical outcomes

Although recent evidence suggests that the clinical benefit may be uncertain for fibrates, a class of drugs used for the treatment of high lipid levels, use of these drugs is common in the U.S. and Canada, with usage increasing steadily in the last decade in the U.S., especially for a brand-name fibrate product, according to a study in the March 23/30 issue of JAMA.

23 Mar 2011

FDA approves Harvest's BMAC System IDE trial to treat non-reconstructable Critical Limb Ischemia

Harvest Technologies Corp. announced today that the FDA has approved the company sponsored 210-patient IDE clinical trial to be conducted at twenty-five sites in the U.S. using the company's proprietary Bone Marrow Aspiration Concentrate (BMAC) System to treat patients with non-reconstructable Critical Limb Ischemia (CLI).

23 Mar 2011

POZEN files motion for Treximet patent litigation against Par

POZEN Inc., a pharmaceutical company committed to transforming medicines that transform lives, today announced that it has filed a motion for a preliminary injunction seeking to prevent Par Pharmaceuticals, Inc. from launching a generic version of Treximet.

23 Mar 2011

Enrollment complete in Aradigm's inhaled ciprofloxacin Phase 2b study in non-cystic fibrosis bronchiectasis

Aradigm Corporation announced the last patient was enrolled in a Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (CFI, ARD-3100) in patients with non-cystic fibrosis bronchiectasis (BE), a severe progressive respiratory disease for which there is currently no approved treatment in the U.S.

23 Mar 2011

Astellas announces positive results from mirabegron phase III trials against OAB

Astellas Pharma Inc. today announced the results of two pivotal phase III clinical trials for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder, show mirabegron significantly improves key OAB symptoms - urinary incontinence and frequency of micturition.

23 Mar 2011

SMR, RTU enter license agreement for RESCULA eye drops

Sucampo Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, Sucampo Manufacturing & Research AG, and R-Tech Ueno, Ltd., a pharmaceutical company founded in Japan in 1989, have entered into a license agreement for RESCULA eye drops, expanding Sucampo's rights beyond its previously agreed territory of the United States and Canada to all countries in Europe and the rest of the world except Japan, Korea, Taiwan and the People's Republic of China.

23 Mar 2011

Milk allergy successfully treated with Xolair

A latest study suggests that children with severe milk allergies may be able to rapidly overcome their sensitivities with the help of a biologic drug that helps to quiet an overly aggressive immune response. This is a small study still waiting to be proved in larger populations say researchers.

22 Mar 2011

Positive results from Meda's Dymista Phase III trial in patients with SAR

Meda announced today positive results from a Phase III clinical trial of Dymista, a novel formulation of azelastine hydrochloride and fluticasone propionate, in patients with seasonal allergic rhinitis.

22 Mar 2011

Placebo News and Research

Aradigm fourth quarter revenue is $144,000 for 2010

Little evidence supporting effectiveness of acupuncture in reducing pain

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Simulated acupuncture can treat nausea effectively in cancer patients undergoing radiotherapy

Study demonstrates superiority of Spiriva over salmeterol in reducing risk of exacerbations in COPD

Opexa's Tovaxin data against MS to be presented at AAN Annual Meeting

Rapid treatment within an hour of injury dramatically cuts bleeding deaths in injured patients

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Cilag, POZEN enter license agreement to develop and commercialize MT 400

Jefferson begins patient recruitment for new clinical trail to prevent colon cancer

MD Anderson receives $2.7 million NCI grant for acupuncture study in cancer

Corticosteroids may decrease occurrence of hospital-acquired pneumonia in ICU patients

Use of fibrates for high lipid levels increases despite uncertain improvement in clinical outcomes

FDA approves Harvest's BMAC System IDE trial to treat non-reconstructable Critical Limb Ischemia

POZEN files motion for Treximet patent litigation against Par

Enrollment complete in Aradigm's inhaled ciprofloxacin Phase 2b study in non-cystic fibrosis bronchiectasis

Astellas announces positive results from mirabegron phase III trials against OAB

SMR, RTU enter license agreement for RESCULA eye drops

Milk allergy successfully treated with Xolair

Positive results from Meda's Dymista Phase III trial in patients with SAR

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News